Clinical trials: Diffuse Parenchymal Lung Diseases
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lung Cancer, Lung Function Decreased
Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
This is a prospective observational study aiming: 1) To quantify lung function using perfusion dual energy computed tomography (DECT) and use this information at the time of treatment planning with preferential sparing of…
- Conditions
- Lung Cancer, Lung Function Decreased, Radiation Pneumonitis
- Trial name
- NCT04863027
- Testing
- Thoracic radiotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania
Idiopathic Pulmonary Fibrosis
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major event of IPF with an annual incidence between 5 and 10% and is responsible for the death of one third of IPF patients.
- Trial name
- EXAFIP (NCT02460588)
- Testing
- Cyclophosphamide, Corticosteroid (prednisolone)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sarcoidosis
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and The World Association of Sarcoidosis and Other Granulomatous Disorders…
- Trial name
- SARCORT (NCT03265405)
- Testing
- Low dose prednisolone, Medium dose prednisolone
- Where
- India
- Volunteers
- 86 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT05572996
- Testing
- Inhaled Treprostinil
- Sponsor
- Ferrer Internacional S.A.
Idiopathic Pulmonary Fibrosis (IPF)
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneously (SC) administered multiple, escalating doses of BG00011 (a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6)…
- Trial name
- NCT01371305
- Testing
- BG00011
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Biogen
Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical…
- Conditions
- Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections
- Trial name
- CaspoNEB (NCT06892951)
- Testing
- Caspofungin Acetate 50 MG, Physiologic saline
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Tours
Rheumatoid Arthritis and Associated Conditions, Lung Diseases, Interstitial
Using Thoracic Ultrasound to Detect Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Background: Pulmonary diseases are significant contributors to morbidity and mortality in patients with rheumatoid arthritis (RA). One of the most common pulmonary manifestation in RA is interstitial lung disease (RA-ILD).
- Trial name
- AURORA (NCT05396469)
- Testing
- National guideline treatment
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Torkell Ellingsen
Sjogren's Syndrome
Interstitial Lung Diseases in Primary Sjogren's Syndrome
Patients with pSS seen in the Division of Rheumatology, the second affiliated hospital of Zhejiang University, School of Medicine (SAHZU) during January 2016 to July 2018, were retrospectively reviewed.
- Trial name
- NCT04978883
- Testing
- No intervention
- Volunteers
- 170 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Vasculitis
Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Treatment of patients with PR3-ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved, maintenance therapy with…
- Trial name
- NCT00128895
- Testing
- azathioprine
- Where
- 8 sites in Netherlands
- Volunteers
- 131 people
- Sponsor
- University Medical Center Groningen
Pulmonary Fibrosis
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT00514683
- Testing
- low dose BIBF1120 once daily, low dose BIBF 1120 twice daily, intermediate dose BIBF 1120 twice daily
- Where
- 92 sites in Argentina, Australia and 23 more
- Volunteers
- 432 people
- Sponsor
- Boehringer Ingelheim
Rheumatic Arthritis, Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis
The aim of the study is to develop a standardized, risk-adapted screening protocol for detecting pleuropulmonary manifestations in patients with rheumatoid arthritis.
- Trial name
- REASSESS (NCT06965322)
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Medical University Innsbruck
Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF)
Hereditary Influences on Pulmonary Fibrosis Trajectories
The SHIFT (Hereditary Influences on Pulmonary Fibrosis Trajectories) study is a prospective, multicenter, observational cohort study designed to investigate familial pulmonary fibrosis (FPF) within the Italian population.
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF), Telomere Disease, Progressive Pulmonary Fibrosis
- Trial name
- SHIFT (NCT07580053)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Clinico Humanitas
Wegener's Granulomatosis, Renal Limited Vasculitis
Anti-Cytokine Therapy for Vasculitis
The purpose of this study is to determine whether Infliximab (monoclonal anti-tumour necrosis factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis.
- Conditions
- Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis
- Trial name
- ACTIVE (NCT00753103)
- Testing
- Infliximab, Cyclophosphamide, Prednisolone
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Rheumatoid Arthritis, Interstitial Lung Disease
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA).
- Trial name
- RAPID (NCT03297775)
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- University of Colorado, Denver
Pulmonary Fibrosis
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid…
- Trial name
- NCT01335477
- Testing
- BIBF 1120
- Where
- 108 sites in United States, Canada and 15 more
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
COPD, Idiopathic Pulmonary Fibrosis (IPF)
Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia
Primary Objective: To evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic…
- Conditions
- COPD, Idiopathic Pulmonary Fibrosis (IPF), Lung Cancer
- Trial name
- RESPIRO (NCT07707245)
- Testing
- Peripheral Blood Collection
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Breathlessness, COPD
Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease
Breathlessness is a common and distressing symptom in patients with advanced diseases like cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) or lung fibrosis, which broadly impacts on patients'…
- Conditions
- Breathlessness, COPD, Cancer, Chronic Heart Failure
- Trial name
- BreathEase (NCT02622412)
- Testing
- Multi-professional breathlessness service (MBS), Delayed MBS Intervention
- Where
- Germany
- Volunteers
- 183 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.